ライフサイエンスコーパス: disease recurrence

1 failure/death during treatment or subsequent disease recurrence).

2 the most predictive features associated with disease recurrence.

3 stage but is correlated to a higher risk of disease recurrence.

4 ormal in 44 (39.3%) patients; 35 (31.3%) had disease recurrence.

5 stoperative PTH also independently predicted disease recurrence.

6 (but not any pair alone) was associated with disease recurrence.

7 colonic cancer surgery increases the risk of disease recurrence.

8 costs, and is characterized by high rates of disease recurrence.

9 orts have described highly variable rates of disease recurrence.

10 Two hundred twenty-one patients had disease recurrence.

11 tion in this phenotypic transition, modeling disease recurrence.

12 ems to improve overall survival and decrease disease recurrence.

13 ified here is a robust prognostic marker for disease recurrence.

14 g AR alone can result in drug resistance and disease recurrence.

15 clinically quiet eye may point to impending disease recurrence.

16 o eradicate residual cancer cells to prevent disease recurrence.

17 hether urine TERT status was an indicator of disease recurrence.

18 ared with clinical findings, to detection of disease recurrence.

19 tcomes are unclear but may be related to HCV disease recurrence.

20 and resistant tumors was a common feature of disease recurrence.

21 accurately reflect a cell's ability to drive disease recurrence.

22 ing or clinical events prompted suspicion of disease recurrence.

23 ations (25.2%), and 32 patients (14.9%) with disease recurrence.

24 t metastasis and is a candidate predictor of disease recurrence.

25 is significantly reduced by the high rate of disease recurrence.

26 of medications used, drug side effects, and disease recurrence.

27 expression correlated with an early time to disease recurrence.

28 d a possible increased risk of primary renal disease recurrence.

29 or to OCR in direct measures of survival and disease recurrence.

30 y but are associated with increased risk for disease recurrence.

31 igh risk of treatment-related morbidity, and disease recurrence.

32 may be associated with reduction in risk for disease recurrence.

33 ril 2010), 435 patients had died and 376 had disease recurrence.

34 nning of cervical cancer and for identifying disease recurrence.

35 re reviewed for liver biopsy to evaluate for disease recurrence.

36 g which frequently changes after therapy and disease recurrence.

37 T) for chronic lymphocytic leukemia (CLL) is disease recurrence.

38 g the probability of acquired resistance and disease recurrence.

39 gnostic factor for poor overall survival and disease recurrence.

40 in clear predictors of postoperative Crohn's disease recurrence.

41 ugs may occur in cancer patients, leading to disease recurrence.

42 modify the course of the disease and reduce disease recurrence.

43 e, and predict the risk of complications and disease recurrence.

44 rvival of residual MM cells, contributing to disease recurrence.

45 gic malignancies frequently fails because of disease recurrence.

46 SH preparations on the important endpoint of disease recurrence.

47 vels of c-Jun expression are associated with disease recurrence.

48 tinent chemotherapeutic targets for reducing disease recurrence.

49 y and inflammation as potential triggers for disease recurrence.

50 nical approaches with the goal of preventing disease recurrence.

51 rimary human prostate cancer predicted early disease recurrence.

52 of Tregs in the eye are important factors in disease recurrence.

53 .0%, respectively), suggesting their role in disease recurrence.

54 n a subset of individuals at higher risk for disease recurrence.

55 gnosis, and identify patients likely to have disease recurrence.

56 the parenchyma were important predictors of disease recurrence.

57 n cancer patients with a low or high risk of disease recurrence.

58 There were 5 patients with disease recurrence.

59 lassification were significant predictors of disease recurrence.

60 thought to contribute to both pain and local disease recurrence.

61 o identify clinicopathological predictors of disease recurrence.

62 Twelve patients (1.9%) experienced disease recurrence.

63 biotics is being actively pursued to prevent disease recurrence.

64 tures in assessing the risk of post-surgical disease recurrence.

65 and response to chemotherapy, and to detect disease recurrence.

66 ded with a striking reduction in the time to disease recurrence.

67 ere it can contribute to drug resistance and disease recurrence.

68 iding sustained benefit through reduction in disease recurrence.

69 culosis (TB) disease are at elevated risk of disease recurrence.

70 treatment are associated with lower risk of disease recurrence.

71 els and the AR/TRIM24 gene signature predict disease recurrence.

72 and even liver transplantation has a risk of disease recurrence.

73 er to monitor treatment response and risk of disease recurrence.

74 ues in restaging for patients with suspected disease recurrence.

75 ons of resistant leukemia cells that mediate disease recurrence.

76 d GSC differentiation and invasive growth in disease recurrence.

77 ies that can identify recipients at risk for disease recurrence.

78 he optimal strategy to prevent postoperative disease recurrence.

79 rsal, with some individuals suffering severe disease recurrence.

80 increase in macrophages/microglia cells upon disease recurrence.

81 lone for prevention of postoperative Crohn's disease recurrence.

82 retinal vascularisation without any signs of disease recurrence.

83 A mismatching was more pronounced on certain disease recurrences.

84 ncer in patients who are suspected of having disease recurrence?

85 Of the 30 patients with disease recurrence, 10 (33%) had recurrence with teratom

86 f 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver.

87 LR group, without significant differences in disease recurrence, 3- or 5-year overall survival(OS) an

88 Similar rates of clinically evident disease recurrence (4% rhTSH vs. 7% thyroid hormone with

89 independently associated with high rates of disease recurrence (4.03 [1.23-13.16], p=0.021) and dise

90 ies was significantly lower in patients with disease recurrence (7.6 % vs 21.3% of biopsies, P = 0.03

91 tumors was an independent predictor of early disease recurrence (adjusted hazard ratio=4.1; 95% confi

92 e of stromal Cav-1 was associated with early disease recurrence, advanced tumor stage, and lymph node

93 B-cell lymphoma and used to predict clinical disease recurrence after frontline treatment.

94 tenin synergizes with imatinib (IM) to delay disease recurrence after imatinib discontinuation and to

95 these areas of unmet needs is prevention of disease recurrence after liver transplantation.

96 cant proportion of sarcoidosis patients have disease recurrence after LT and presence of active granu

97 At disease recurrence after nephrectomy for localized disea

98 EST expression is negatively correlated with disease recurrence after prostatectomy, invite a deeper

99 Biochemical disease recurrence after radical prostatectomy often pro

100 positive resection margin is a predictor of disease recurrence after resection of colorectal liver m

101 Disease recurrence after surgery and/or radiation and di

102 Predictors of Crohn's disease recurrence after surgery include cigarette smoki

103 h cells were associated with shorter time to disease recurrence after surgery.

104 ges; cutoff criteria were defined to predict disease recurrence after surgery.

105 after liver transplantation, graft loss from disease recurrence after transplantation is uncommon.

106 Although 30%-50% of these patients suffer disease recurrence after transplantation, with poor long

107 Additionally, factors which may predict disease recurrence along with the implications of these

108 ignificantly reduced risk of PSA relapse and disease recurrence, although the improvements in metasta

109 ce a variety of challenges as they cope with disease recurrence and a myriad of normal tissue complic

110 currence Score (RS) assay is used to predict disease recurrence and benefit of chemotherapy in estrog

111 tatectomy is associated with a lower risk of disease recurrence and better prostate cancer specific m

112 The risks of disease recurrence and bone metastasis were also signifi

113 sustained benefits in terms of reduction of disease recurrence and breast cancer mortality.

114 The aim of the current study is to describe disease recurrence and clinical course after LT.

115 ne and were followed up until March 2007 for disease recurrence and death (median follow-up, 5.6 year

116 Patients were observed until March 2009 for disease recurrence and death.

117 pants was not associated with a reduction of disease recurrence and death.

118 ove prediction for patients at high risk for disease recurrence and death.

119 ssion of TSGs strongly correlates with early disease recurrence and decreased overall survival.

120 However, disease recurrence and development of metastatic disease

121 e data sets and is by itself associated with disease recurrence and disease-specific survival.

122 icantly enhanced its predictive accuracy for disease recurrence and disease-specific survival.

123 12 rate (85%) including patients with severe disease recurrence and F3-4 cirrhosis.

124 peutic options for patients at high risk for disease recurrence and found a clinically important rela

125 transplantation, there is very high risk of disease recurrence and graft loss.

126 been used for diagnosis and surveillance of disease recurrence and imaging has revolutionised oncolo

127 cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary tr

128 ding of preoperative parameters that predict disease recurrence and inclusion of concomitant subvalvu

129 elevated, correlating with prolonged time to disease recurrence and inversely correlating with tumor

130 The rates of HCV-related disease recurrence and liver fibrosis progression among

131 conducted to investigate the impact of AL on disease recurrence and long-term survival.

132 he prognostic significance of CTC status for disease recurrence and melanoma-specific survival (MSS).

133 ve also suggested their potential to prevent disease recurrence and metastases.

134 Low levels of SOCS2 correlated strongly with disease recurrence and metastasis in clinical specimens.

135 of Ron receptor activation, correlates with disease recurrence and metastasis in patients.

136 stem cell phenotype, which is implicated in disease recurrence and metastasis.

137 nt tumours correlates with increased risk of disease recurrence and metastatic PCa.

138 iation of diabetes with an increased risk of disease recurrence and mortality in the setting of colon

139 mic p23 expression more accurately predicted disease recurrence and mortality than did stage alone.

140 ould help to identify those at high risk for disease recurrence and mortality, who could benefit from

141 Risks of disease recurrence and non-RCC death were estimated by u

142 h nuclear STAT5A/B expression predicts early disease recurrence and PCa-specific death in clinical PC

143 associated with rates of clinically evident disease recurrence and persistent uptake in the thyroid

144 n preoperative CECT is associated with early disease recurrence and poor OS and may be useful for ide

145 pression was associated with advanced stage, disease recurrence and poor prognosis.

146 regional lymph nodes indicates high risk of disease recurrence and poor survival in node-negative CR

147 odes is associated with an increased risk of disease recurrence and poor survival in patients with no

148 ma specimens were associated with more rapid disease recurrence and poorer overall survival.

149 , and HER2 expression is predictive of human disease recurrence and prognosis.

150 ith a special focus on areca nut chewing, on disease recurrence and progression in patients with non-

151 thermore, we find that IPO11 status predicts disease recurrence and progression to metastasis in pati

152 ary cytology in the same setting, predicting disease recurrence and progression, and predicting and m

153 igh-risk NMIBC is the prevention or delay of disease recurrence and progression.

154 but a majority will subsequently experience disease recurrence and require further surgery.

155 nd metastatic lymph nodes as well as between disease recurrence and scars or adverse reactions after

156 ssion clinically correlated with tumor size, disease recurrence and survival rate.

157 Long-term follow-up data for disease recurrence and survival was collected in six par

158 Due to both the patterns of disease recurrence and the adverse effects of treatments

159 umor miR-106b expression was associated with disease recurrence and the combination of high miR-106b

160 vides the first link between protection from disease recurrence and the humoral response to Hla, a vi

161 h implications for improved understanding of disease recurrence and therapeutic response.

162 r infants at risk for increased mortality or disease recurrence and to further the knowledge of the u

163 refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions

164 withdrawn for 16-36 months (tolerant), 2 had disease recurrence, and 3 had subclinical rejection in p

165 Outcomes of interest included survival, disease recurrence, and adverse events.

166 A mismatches and hepatic allograft survival, disease recurrence, and immunosuppression interactions.

167 r underlying cause of therapy resistance and disease recurrence, and is a read-out of tumor growth.

168 Nodal burden, disease recurrence, and overall survival.

169 NSCLC) and correlates with tumor metastasis, disease recurrence, and poor survival in patients with N

170 iation between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with

171 er diagnosis in relation to quality of life, disease recurrence, and survival.

172 expression in primary PCa is correlated with disease recurrence, and this study found that Pin1 expre

173 lay a significant role in tumor progression, disease recurrence, and treatment failure.

174 er these SNPs affect the age of onset of the disease, recurrence, and survival.

175 late primary, adjuvant, and salvage therapy; disease recurrence; and survival in patients with T1/T2

176 ion between specific immunologic markers and disease recurrence are needed to ultimately develop targ

177 the possibility that the drug resistance and disease recurrence associated with imatinib treatment of

178 The probability of remaining free of disease recurrence at 5 and 10 years was 83% and 80%, re

179 Radical prostatectomy reduced disease recurrence at 5 years compared with external-bea

180 k groups, and to predict their risk of early disease recurrence at diagnosis.

181 ial, received some trial therapy, and had no disease recurrence at the end of a symptom assessment pe

182 ter surgery, but was higher in patients with disease recurrence (based on endoscopic analysis; Rutgee

183 th increased malignancy, poor prognosis, and disease recurrence, but the underlying causes of PMT are

184 g patients in PREVENT1, 53%-63% did not have disease recurrence, compared with 65% of those given pla

185 n PREVENT2, 59%-69% of patients did not have disease recurrence, compared with 68% of those given pla

186 omosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant

187 cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy an

188 Disease recurrence did not correlate with graft survival

189 t was safely interrupted with no evidence of disease recurrence during 8-37 mo (mean, 23 mo).

190 prostate cancer, with upwards of 65% having disease recurrence even after primary treatment.

191 tient with metastatic melanoma who developed disease recurrence following an initial, unequivocal rad

192 ients at high risk of lymphoma relapse after disease recurrence following prior autologous transplant

193 Excellent long-term disease recurrence-free survival can be achieved in sele

194 ith unresectable ICCA demonstrated promising disease recurrence-free survival.

195 recurrent disease, ACR did not develop once disease recurrence had been seen on transbronchial biops

196 were all associated with high probability of disease recurrence (hazard ratio 2.24 [95% CI 1.51-3.32]

197 s the risk of death due to causes other than disease recurrence (hazard ratio, 1.25; 95% CI, 1.00 to

198 tics that are associated with a high rate of disease recurrence, highlighting the need for novel trea

199 AL may be a risk factor for disease recurrence, however available studies have been

200 reatment, patients were classified as having disease recurrence if cultures grew MDR-TB or they re-in

201 followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD

202 ogression and were independent predictors of disease recurrence in a cohort of 141 patients with AJCC

203 actors for disease-free survival and time to disease recurrence in a cohort of patients with axillary

204 in modification impacted on colonization and disease recurrence in a murine model of infection, showi

205 erexpression is a novel molecular marker for disease recurrence in breast cancer patients and may ser

206 re, shape, and tumor architecture to predict disease recurrence in early stage NSCLC from digitized H

207 s, as well as with metastatic competence and disease recurrence in multiple clinical cohorts.

208 event and treat acquired chemoresistance and disease recurrence in OC and enhance the efficacy of sta

209 xpression has been reported to be a cause of disease recurrence in osteosarcoma.

210 veloped nomogram was demonstrated to predict disease recurrence in patients with LMS which may allow

211 The median time-to-disease recurrence in patients with low MYO1A was 1 y, c

212 methods were used to generate a signature of disease recurrence in patients with resected early stage

213 riant allele were highly associated with the disease recurrence in patients with Tis, Ta, and T1 tumo

214 to be effective for end-stage liver disease, disease recurrence in the allograft is a controversial t

215 trogen receptor (ER) alpha signaling prevent disease recurrence in the majority of patients with horm

216 In particular, how disease recurrence in the renal allograft defines graft

217 vity is highly predictive of post-transplant disease recurrence in this pediatric patient population.

218 ectomy does not improve survival or decrease disease recurrence in women with early-stage, low-grade

219 Importantly, disease recurrence includes both early and late events,

220 The hazard ratios for disease recurrence increased incrementally based on the

221 nk4a expression was strongly associated with disease recurrence, independent of standard histopatholo

222 Two of these patients had systemic disease recurrence involving the primary malignant site.

223 is with high risk for asthma comorbidity and disease recurrence is characterized by type 2 inflammato

224 The risk of disease recurrence is minimized and survival often prolo

225 Disease recurrence is not an insignificant event because

226 vertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage stra

227 ve/HER2-negative BC, with the early spike in disease recurrence markedly decreased.

228 Identification of protein markers linked to disease recurrence may yield insights into tumor biology

229 on; HR, 0.43; 95% CI, 0.31-0.58; P<.001) and disease recurrence (median recurrence-free survival, 13.

230 cer stem cells (CSC) have been implicated in disease recurrence, metastasis, and therapeutic resistan

231 SC debulking surgery (n = 14) or patients at disease recurrence (n = 16).

232 ring a mean observation period of 21 months, disease recurrence occurred in 140 patients (57.9%).

233 Disease recurrence occurred in 171 patients (7.1%) in th

234 en every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic eff

235 onal year of follow-up, the hazard ratio for disease recurrence or death in the capecitabine group wa

236 Disease recurrence or death occurred in 377 patients in

237 f 3.2 years, 69 patients (22%) experienced a disease recurrence or death.

238 median of 24 months (range, 2-63 months) for disease recurrence or death.

239 as the time from random assignment to local disease recurrence or death.

240 ed to take place after 214 or more events of disease recurrence or deaths before recurrence had occur

241 may serve as a nidus for recolonization and disease recurrence or for the development of furcation c

242 Markers can report on the risk of disease recurrence or metastasis, or treatment responsiv

243 therapy plus trastuzumab with no evidence of disease recurrence or metastatic disease at study entry.

244 nt was given continuously for 1 year, unless disease recurrence or new breast cancer, intolerable adv

245 icacy in breast cancer patients who have had disease recurrence or progression after tamoxifen.

246 tases are an important prognostic factor for disease recurrence or survival among patients with breas

247 fied into two groups: those at high risk for disease recurrence or the need for immunosuppressive tre

248 f 6.3 years, there were 165 events involving disease recurrence or the occurrence of contralateral br

249 CI; 89 to 93) with placebo (hazard ratio for disease recurrence or the occurrence of contralateral br

250 eriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisa

251 eriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureu

252 ved placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1

253 FDG-PET/CT was utilized for surveillance of disease recurrence outside the regional field of treatme

254 CCCG) risk classification were predictors of disease recurrence (P < .0005 and = .001, respectively).

255 nce of mutDNA detection during NAC predicted disease recurrence (p = 0.003), emphasising its potentia

256 quately the relationship between subtype and disease recurrence, particularly when there is a substan

257 ormance for detecting LNM preoperatively and disease recurrence postoperatively in endometrial cancer

258 s post-random assignment, 40% had documented disease recurrence prior to death.

259 ctomy predicted markedly poorer survival and disease recurrence profiles.

260 f early tissue changes in the time-course of disease recurrence provides a unique insight into the in

261 Disease recurrence remains the main cause of treatment f

262 Because disease recurrence remains the major cause of treatment

263 tment is liver transplantation, and risk for disease recurrence remains.

264 chieved a pCR were less likely to experience disease recurrence (RFS, 86%) than those who did not ach

265 stic outcomes nomogram to predict the 5-year disease recurrence risk after radical cystectomy.

266 provide more accurate information to assess disease recurrence risk and BC-related death.

267 -ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.

268 .7% in the tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.

269 HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planne

270 eocolonoscopy for early detection of Crohn's disease recurrence should be part of any postoperative m

271 n of the mutations with patient survival and disease recurrence, subject to modification by a common

272 odel was most sensitive to assumptions about disease recurrence, survival, and the health utility red

273 nfavorable features, one-half of whom had no disease recurrence, survived at least 6 years, in contra

274 was lower (31 vs 83 months, P = 0.001), with disease recurrence that was more frequent (50.8% vs 32.7

275 ting that TAMs contribute to prostate cancer disease recurrence through paracrine signaling processes

276 RB-pathway biology that are associated with disease recurrence through the epithelial or stromal com

277 on, 2-weeks-off schedule for 1 year or until disease recurrence, unacceptable toxicity, or consent wi

278 01; HR for LN SUV(max), 1.32, P = 0.004) and disease recurrence (univariate analyses: HR for PT SUV(m

279 stasis to distant organ sites and more rapid disease recurrence upon removal of the primary tumor.

280 however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is disco

281 Median survival after first disease recurrence was 27.7 months with thalidomide-pred

282 involved lymph nodes on the risk of systemic disease recurrence was assessed using univariate and mul

283 Early disease recurrence was associated with a markedly increa

284 Disease recurrence was diagnosed by biopsy (protocol or

285 Disease recurrence was experienced in 14 patients (2.3%)

286 ng of tissues from patients with and without disease recurrence was performed for Ki-67 and the macro

287 Disease recurrence was retrospectively assessed a median

288 Renal disease recurrence was scored using the histopathologica

289 Biopsy-proven glomerular disease recurrence was similar in patients induced with

290 osed cells of origin for prostate cancer and disease recurrence, we looked further into this amplific

291 Hazard ratios (HRs) for disease recurrence were generated using Cox proportional

292 A total of 361 instances (83%) of disease recurrence were observed after a median follow-u

293 we demonstrated that vancomycin only delayed disease recurrence, whereas neutralizing polysera agains

294 remission than in samples from patients with disease recurrence, which indicates that SET9 acts as a

295 It predicts which patients will have disease recurrence with greater accuracy than CRP level

296 ntolerant to first-line chemotherapy, or had disease recurrence within 1 year of adjuvant therapy for

297 zed studies to uncover mechanisms leading to disease recurrence within each individual patient are wa

298 disease categories except where the risks of disease recurrence within the first year are low, but wi

299 However, 33% of these patients had disease recurrence within the next 2 years.

300 m (ie, cured), and those who will experience disease recurrence within their lifetime (ie, susceptibl